1963. The mean serum urate concentration during an acute attack was 0 49 mmol/l (8-2 mg/100 ml), but there were 10 men, additional to those described here, whose levels ranged from 0-24 to 0-38 mmol/l (4-0 to 6-4 mg/100 ml) and who were taking no drugs. A further three patients, including one woman, had concentrations of 0-22, 0-24, and 0-25 mmol/l (3 7, 4 0, and 4-2 mg/100 ml) respectively but were taking phenylbutazone or probenecid.
3Hall, A P, et al, American Journal of Medicine, 1967, 42, 27. 4 Hadler, N M, et al, American Journal of Medicine, 1974, 
Response of patients offered influenza vaccination by injection and by nasal insufflation
Vaccination against influenza has been advocated particularly in those who are at risk from complications of infection. In the present study "at risk" patients in a general practice with 5400 patients in a residential area in the suburbs of Glasgow were identified using a feature card retrieval system1 2 and offered vaccination either subcutaneously or intranasally. Patients included were those in the 70 years and over age group, those with chronic chest or heart disease, and patients taking steroids. Four hundred and thirty-four such patients were identified. The aim was to determine the number of patients at risk; the number who accepted the offer of influenza immunisation; whether the form of immunisation affected the response rate; and to compare the response in the "at risk" patients with those in a "healthy" group.
The study "At risk" patients were randomly allocated to one of two groups, those from the same family being allocated to the same group. The 228 patients ingroup A were sent a letter which invited them to attend the surgery without an appointment for immunisation by nasal insufflation, using a killed virus vaccine insufflation manufactured by Duphar Laboratories. The 206 patients in group B were invited to telephone to arrange an appointment for influenza vaccination by injection. Overall, about one-third of the patients accepted the offer of immunization (table). In the group of patients with disease about one-half responded, compared with just over a quarter in the 70 and over age group. There was no significant difference in the response rate between those offered immunisation by injection and those offered immunisation by insufflation.
A further 310 "healthy" patients in the age group 50-69 were selected from the practice. This group was subdivided randomly into two groups, one group being offered immunisation by injection and the other immunisation by insufflation. As with the "at risk" group, overall about one-third ofthe patients responded. Nevertheless, in this group more patients responded to the offer of immunisation by insufflation (37 %) than to immunisation by injection (23 %)-a significant difference (P< 0 01).
Discussion
While immunisation of patients at risk from influenza (estimated in this study to be about 8%h of the practice) is widely advocated, this Comment ACTH release is controlled by the hypothalamus, and serotonin may act as a transmitter. In Cushing's disease the underlying fault is in hypothalamic regulation, and other abnormalities of hypothalamic function, such as loss of diurnal variation in growth hormone and prolactin concentrations, abnormal growth hormone responsiveness to hypoglycaemia, and an abnornal sleep EEG, may be found.3
Cyproheptadine is a centrally acting serotonin antagonist that blocks hypoglycaemia-induced cortisol secretion.4 Its use in hypothalamopituitary-mediated Cushing's disease seems logical and theoretically provides a treatment of Cushing's disease that avoids bilateral adrenalectomy and reduces the risk of Nelson's syndrome. Its use was unsuccessful in our patient. Krieger recently reported5 that out of 40 patients with pituitary-dependent Cushing's disease, some 601o were successfully treated with cyproheptadine; she also reported successful treatment of three out of four patients with Nelson's syndrome. One of her patients, however, who had a normal proportion of slowwave sleep failed to respond to cyproheptadine. This was also the case in our patient. Perhaps the sleep EEG will be useful in predicting which patients will respond to cyproheptadine.
Pruritus as a presentation of myelomatosis
Cutaneous manifestations of plasma cell dyscrasia are uncommon but have been the subject of several reports.1 2 We report two patients who presented with generalised pruritus in whom diagnoses of myelomatosis were unequivocally established. To our knowledge, this association is unreported. The diagnostic criteria for myelomatosis were therefore fulfilled. Treatment was initiated with intermittent melphelan (0 25 mg/kg/day) and prednisolone (60 mg/day) for four consecutive days at six-week intervals. Pruritus cleared rapidly after chemotherapy but recurred some ten days before the second pulse became due. A similar sequence of events followed this pulse of chemotherapy but subsequently the patient remained free from pruritus. Biochemical evidence of response was also obtained, with the IgG concentration falling to 20 g/l and other immunoglobulins rising to normal. Eighteen months after starting treatment the patient remains in good health without further pruritus.
Case 2-An 87-year-old retired engineer presented with a one-year history of generalised pruritus and occasional night sweats. He had varicose eczema and mild oedema of both legs, areas of lichenification, and generalised excoriation. Investigation showed a raised ESR (110 mm in 1 h, Westergren), a mild normochromic normocytic anaemia (Hb 11 g/dl), and slight thrombocytopenia of 76-0 x 109/1. Serum globulins were increased at 41 g/l. Electrophoresis showed a paraprotein band and immunoglobulin quantitation showed a raised IgA level of 20-1 g/l. Bence Jones protein was absent and skeletal survey negative. Bone marrow examination showed a definite infiltrate of immature and atypical plasma cells, confirming the diagnosis. The results of all other investigations to establish the presence of an underlying systemic disease were negative. A similar chemotherapeutic regimen of melphelan and prednisolone was started and within four months pruritus had cleared completely. Insufficient time has elapsed to assess fully the response to treatment.
